View Post

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

In In The News by Barbara Jacoby

Source: University of Illinois at Urbana-Champaign From: news-medical.net A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those …

View Post

EMERALD Trial: Elacestrant vs Standard Endocrine Therapy in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

In In The News by Barbara Jacoby

By: Matthew Stenger From: ascopost.com As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor (ER) degrader elacestrant vs standard endocrine therapy among patients with previously treated ER-positive, HER2-negative advanced breast cancer, including those with an ESR1 mutation. Elacestrant …

View Post

Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022

In In The News by Barbara Jacoby

From: businesswire.com Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 inhibitory activity) in patients with locally advanced or metastatic breast cancer (mBC) Tenalisib was well tolerated and showed encouraging preliminary efficacy as a single agent in both primary and secondary resistant mBC; Data …

View Post

Trial of Odetiglucan Plus Pembrolizumab for Metastatic Breast Cancer Starts Dosing

In In The News by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com Treatment with the combination of odetiglucan or Imprime PGG and pembrolizumab had begun in patients with metastatic hormone-refractory breast cancer who are enrolled in a phase 2 clinical trial. The first patients with metastatic hormone-refractory breast cancer in a phase 2 study have been dosed with the combination of odetiglucan (Imprime PGG) and pembrolizumab (Keytruda), …

View Post

NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center

In In The News by Barbara Jacoby

New clinical trial is focused on novel therapy for triple negative breast cancer When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused …

View Post

Eribulin Is Well Tolerated in Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: M. Alexander Otto, MMS, PA From: medscape.com The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaways In a postmarketing study, eribulin (Halaven) was well tolerated by patients with metastatic breast cancer, with few women discontinuing because of adverse events. However, two single-nucleotide polymorphisms (SNPs) were associated …

View Post

Phoenix Molecular Designs Successfully Completes Patient Enrollment in Phase 1/1b Clinical Trial of PMD-026

In In The News by Barbara Jacoby

Source: Phoenix Molecular Design From: PR Newwire Phoenix Molecular Designs (PhoenixMD), a clinical stage biopharmaceutical company dedicated to developing precise cancer therapeutics, today announced the completion of patient enrollment and dosing of PMD-026 in their Phase 1b monotherapy clinical trial. The successful completion of patient enrollment in this Phase 1/1b trial is an important step forward for PhoenixMD as they advance …

View Post

NIH study advances personalized immunotherapy for metastatic breast cancer

In In The News by Barbara Jacoby

From: nih.gov An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast cancer …

View Post

Elacestrant Impresses in EMERALD Trial of Breast Cancer

In In The News by Barbara Jacoby

By: Kate O’Rourke From: generalsurgerynews.com New research from the EMERALD trial shows that elacestrant (Radius Health) is the first oral selective estrogen receptor degrader to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival versus standard-of-care endocrine therapy, in breast cancer. The findings come from a phase 3, randomized trial in men and postmenopausal women with estrogen receptor …

View Post

Brufsky Underscores Practicing-Changing Data in HER2+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Jessica Hergert From: onclive.com The data that emerged from the phase 3 DESTINY-Breast03 trial (NCT03529110) represent a significant advancement in the field of metastatic HER2-positive breast cancer, said Adam M. Brufsky, MD, PhD, FACP, who added that the tripling of progression-free survival (PFS) seen with fam-trastuzumab deruxtecan-nxki (Enhertu) vs ado-trastuzumab emtansine (T-DM1; Kadcyla) will change the natural history of …